Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

SNDX Syndax Pharmaceuticals Inc

14,24

0,00 (0,00%)

29 Jan 2025 - Fechado

Atrasado em 15 minutos

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals (NASDAQ:SNDX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Syndax Pharmaceuticals.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Syndax Pharmaceuticals.

Notícias Syndax Pharmaceuticals Inc

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Quarta, 22 de Janeiro de 2025 (1 semana atrás) • Edgar (US Regulatory)

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Quarta, 15 de Janeiro de 2025 (2 semanas atrás) • PR Newswire (US)

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Segunda, 13 de Janeiro de 2025 (2 semanas atrás) • PR Newswire (US)

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Terça, 7 de Janeiro de 2025 (3 semanas atrás) • PR Newswire (US)

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Terça, 7 de Janeiro de 2025 (3 semanas atrás) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sexta, 3 de Janeiro de 2025 (4 semanas atrás) • PR Newswire (US)

Form 8-K - Current report
Sexta, 20 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Segunda, 9 de Dezembro de 2024 (2 meses atrás) • PR Newswire (US)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Sábado, 7 de Dezembro de 2024 (2 meses atrás) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sexta, 6 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Terça, 3 de Dezembro de 2024 (2 meses atrás) • PR Newswire (US)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Quarta, 27 de Novembro de 2024 (2 meses atrás) • PR Newswire (US)

Mais Notícias de Syndax Pharmaceuticals Inc

Índice Bovespa

Agrogalaxy Participacoes ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições